The generation and use of transgenic and gene-targeted mice has become an essential technology for basic cancer research, as well as for other areas of basic biomedical research. Therefore, this facility serves two critical functions within the Cancer Center. First, the Animal Facility provides convenient, affordable and high quality animal care and maintenance to Cancer Center investigators who use transgenic, mutant and other experimental mice in their research. The support for this Facility provided by the Cancer Center, as well as by the University, results in animal maintenance charges that are relatively affordable, which is a prerequisite for genetic studies using large numbers of transgenic and mutant mice. Second, the Facility operates a transgenic and chimeric mouse production service, which allows all Cancer Center investigators to generate new strains of transgenic mice or perform gene targeting (e.g., gene knockout) studies. The Facility provides technical advice on the design and construction of transgenes and gene-targeting vectors. DNA constructs for transgenesis, and genetically modified ES cell lines are produced by individual Cancer Center investigators, then delivered to the facility, where they are injected into mouse eggs or blastocysts, respectively. The resulting mice are then returned to the individual investigators for further analysis and breeding. The Facility also plans to provide cryopreservation of mouse embryos, and to produce new wild type ES cell lines for use by investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013696-30S2
Application #
6665592
Study Section
Project Start
2002-07-23
Project End
2003-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
30
Fiscal Year
2002
Total Cost
$296,752
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Sones, Jennifer L; Merriam, Audrey A; Seffens, Angelina et al. (2018) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J 32:2574-2586
Park, Karen Sophia; Xu, Christine L; Cui, Xuan et al. (2018) Reprogramming the metabolome rescues retinal degeneration. Cell Mol Life Sci 75:1559-1566
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793

Showing the most recent 10 out of 331 publications